Huntington's Disease Research

Huntington's disease is a neurodegenerative disease characterized by cognitive decline and motor dysfunction. It is a genetic disorder which results in the production of mutant huntingtin protein (mHtt). This protein aggregates in the cell cytoplasm and nucleus, affecting cellular function.

Huntington's Disease Research Products Targets

Products for Huntington's Disease Research - Page 33

Cat.No. Product Name Information/Activity
BCC4514 Tyrphostin AG 879 Tyrphostin AG 879 (AG 879) is a tyrosine kinase inhibitor that inhibits TrKA phosphorylation (IC50 of 10 μM), but not TrKB and TrKC. Tyrphostin AG 879 is also a selective ErbB2 tyrosine kinase inhibitor with an IC50 of 1 μM, and has at least 500-fold higher selectivity to ErbB2 than EGFR. Tyrphostin AG 879 has anticancer activity.
BCC3668 GNF-5837 GNF-5837 is a potent, selective, and orally bioavailable pan-tropomyosin receptor kinase (TRK) inhibitor which display antiproliferative effects in cellular Ba/F3 assays ( IC50 values of 7 nM, 9 nM and 11 nM for cells containing the fusion proteins Tel-TrkC, Tel-TrkB and Tel-TrkA, respectively) .
BCC5093 GW441756 GW 441756 is a specific Tropomyosin-related kinase A (TrkA) inhibitor with an IC50 value of 2 nM; little activity to c-Raf1 and CDK2.
BCC7189 Demethylasterriquinone B1 78860-34-1
BCC5872 NTR 368 197230-90-3
BCC7307 Ro 08-2750 Ro 08-2750 is a non-peptide and reversible nerve growth factor (NGF) inhibitor which binds to NGF, and with an IC50 of ~ 1 µM. Ro 08-2750 inhibits NGF binding to p75NTR selectively over TRKA. Ro 08-2750 is a selective MSI RNA-binding activity inhibitor, with an IC50 of 2.7 μM.
BCC2405 TLQP 21 869988-94-3
BCC8024 Rose Bengal Potent VGlut and VMAT inhibitor; cell permeable
BCC7799 FFN 511 1004548-96-2
BCC6590 (1S,3R)-ACPD 111900-32-4